about
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitorsAnalysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine modelA clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probandsGermline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromesClinical and molecular features of young-onset colorectal cancerPrecision targeted therapy of ovarian cancerEpidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancerMultiple endocrine neoplasia type 2: an overviewNuclear PTEN levels and G2 progression in melanoma cellsPhelan-McDermid Syndrome and SHANK3: Implications for Treatment.The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment.Bannayan-Riley-Ruvalcaba syndrome: MRI neuroimaging features in a series of 7 patients.Germline disruption of Pten localization causes enhanced sex-dependent social motivation and increased glial production.Involvement of members of the cadherin superfamily in cancerHereditary hamartomatous polyposis syndromes: understanding the disease risks as children reach adulthood.Increased prevalence of eosinophilic gastrointestinal disorders in pediatric PTEN hamartoma tumor syndromesThe nutritional phenome of EMT-induced cancer stem-like cellsIdentification of cancer cell-line origins using fluorescence image-based phenomic screening.Selection of extreme phenotypes: the role of clinical observation in translational research.Naturally occurring germline and tumor-associated mutations within the ATP-binding motifs of PTEN lead to oxidative damage of DNA associated with decreased nuclear p53.Evidence for an hMSH3 defect in familial hamartomatous polyps.Frequency of germline PTEN mutations in differentiated thyroid cancer.PTEN hamartoma tumor syndrome: an overview.Medullary thyroid carcinoma: molecular signaling pathways and emerging therapiesIncidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterationsGermline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53.Prospective comparison of family medical history with personal genome screening for risk assessment of common cancers.Papillary renal cell carcinoma is associated with PTEN hamartoma tumor syndromeDeveloping multi-target therapeutics to fine-tune the evolutionary dynamics of the cancer ecosystem.A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancerCo-clustering phenome-genome for phenotype classification and disease gene discovery.Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation.Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypesPediatric Medullary Thyroid CarcinomaDifferential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndromeEstimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndromeFrequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers.Cowden syndrome-related mutations in PTEN associate with enhanced proteasome activity.ATP modulates PTEN subcellular localization in multiple cancer cell lines.Prognostic molecular biomarkers for cutaneous malignant melanoma
P2860
Q21184033-DB5A551F-9625-4036-8899-24A0478E7C46Q22337253-F32A0B70-6ABF-465B-B0A9-21C7C7F14005Q24606333-0224B670-617B-41D7-9279-FED7A081E61CQ24649528-704DF3AD-543F-4D0F-A152-306D95DCC4A5Q26768431-21228CE5-71E2-490F-A9E7-ABEC8DF02F6AQ28078658-286F1B50-B0B2-4169-B38C-8CC47069FFCAQ28084216-E8285743-8D14-49C1-8D10-BC482D64D8C6Q28237010-B4C41737-9F43-43AA-966D-F47FD2CB71D3Q28391204-11AE776C-02B2-4384-8EF6-92C17EF28E37Q30009184-03BBD641-76A2-4D20-8038-74203554149BQ30234889-768C7CA1-19B7-4E42-926A-86EF42FB1AE5Q30658679-7A764288-6BAF-4961-A897-B0E3929442CAQ33649301-B89AAF3E-36DC-43EF-8920-4BDD3FEA76FBQ33899441-F0B53583-89F1-42C6-BA3F-39A99593DD83Q33916338-75C8DBFC-A119-4BF6-BC2C-D088A96956F2Q34030947-95EFAB7B-501F-4A6E-896B-AEA193BB2B84Q34100815-4940A86B-E759-4BDE-B52A-D5F73BD00CD0Q34182256-D61F1012-1DEF-4AE6-BDE7-D28DC4608B86Q34384968-66AFD7F1-8DF8-4BA4-9796-CC27C4C51400Q34399395-16DF4BAF-63FE-4E4C-AAA8-DA4E3F50D13CQ34420082-450521FB-705B-43C0-85AA-A8D35509B2EEQ34975154-1BA8E3B3-F444-4098-ACE6-46216B24ECC3Q34996547-A2B3F4AB-9113-47EE-95DB-84EAB1759B7AQ35038893-578C880C-2D9A-478F-B345-07B58C9944EDQ35597950-35CB2A45-2CC8-48EC-923F-A11F909F3974Q35747115-E1C80ED4-7B16-4E8B-8CD0-4E5E52CB4F0FQ35899320-E1E89B4F-2738-4EEA-8F87-461CC6AE431DQ35925866-468357C4-F531-4306-BDB1-A0E488B007E9Q36097745-A5FF1E67-9734-4D8C-A3D2-FB364A097316Q36237554-25763ABC-9254-43C8-AEDE-4D0FA226A321Q36341451-D166EC3B-9146-435E-BD17-F4AD11472ED7Q36430799-AC6AE82E-C7DE-4618-830C-362ACBE5541AQ36442445-806BA7AE-EBE6-4063-AD17-F0A316A81C4EQ36715586-E64F10CB-F5E4-4C89-8A79-9F8A136B5A03Q36718983-C1E43CC1-CEC7-4A87-924F-99AA37C07C33Q36837037-7C8EF0D5-97D7-4846-949D-860DA8DC11FDQ36839671-9C6F9271-906C-435A-BBC6-0ED1ACC4B817Q36847305-3389F661-D8A2-489A-B622-12E1946245EDQ36851633-0EF3E6FB-0B8A-434A-A48A-181739DF3D20Q36905877-C8F25CA4-D606-47F6-91F9-45E9426265AA
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Cancer phenomics: RET and PTEN as illustrative models
@ast
Cancer phenomics: RET and PTEN as illustrative models
@en
Cancer phenomics: RET and PTEN as illustrative models
@nl
type
label
Cancer phenomics: RET and PTEN as illustrative models
@ast
Cancer phenomics: RET and PTEN as illustrative models
@en
Cancer phenomics: RET and PTEN as illustrative models
@nl
prefLabel
Cancer phenomics: RET and PTEN as illustrative models
@ast
Cancer phenomics: RET and PTEN as illustrative models
@en
Cancer phenomics: RET and PTEN as illustrative models
@nl
P356
P1476
Cancer phenomics: RET and PTEN as illustrative models
@en
P2093
Charis Eng
Kevin M Zbuk
P2888
P356
10.1038/NRC2037
P407
P577
2007-01-01T00:00:00Z
P6179
1050503273